KalVista initiates Phase 3 KONFIDENT trial of KVD900 for HAE attacks

KalVista Pharmaceuticals, Inc.

KVD900 is first potential oral on-demand therapy for HAE; all current on-demand therapies are injectable.
Trial is double-blind, placebo-controlled, crossover; two doses (300 mg, 600 mg) vs placebo.
Primary endpoint: time to beginning of symptom relief per Patient Global Impression of Change (PGI-C) scale.
Enrollment: minimum 84 adolescent and adult patients at ~60 sites in 20 countries.
Top-line data expected in second half of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.